Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 159

4.

Topoisomerase IIalpha expression in breast cancer: correlation with outcome variables.

Depowski PL, Rosenthal SI, Brien TP, Stylos S, Johnson RL, Ross JS.

Mod Pathol. 2000 May;13(5):542-7.

5.

Adrenocortical neoplasms: role of prognostic markers MIB-1, P53, and RB.

Vargas MP, Vargas HI, Kleiner DE, Merino MJ.

Am J Surg Pathol. 1997 May;21(5):556-62.

PMID:
9158680
6.

Prognostic indicators of malignancy in adrenal pheochromocytomas: clinical, histopathologic, and cell cycle/apoptosis gene expression analysis.

Strong VE, Kennedy T, Al-Ahmadie H, Tang L, Coleman J, Fong Y, Brennan M, Ghossein RA.

Surgery. 2008 Jun;143(6):759-68. doi: 10.1016/j.surg.2008.02.007. Epub 2008 Apr 14.

PMID:
18549892
7.

Immunohistochemical estimations of growth activity to predict biological behavior of pheochromocytomas.

Nagura S, Katoh R, Kawaoi A, Kobayashi M, Obara T, Omata K.

Mod Pathol. 1999 Dec;12(12):1107-11.

PMID:
10619262
8.
9.

Expression of p53, Ki-67, E-cadherin, N-cadherin and TOP2A in triple-negative breast cancer.

Nakagawa M, Bando Y, Nagao T, Morimoto M, Takai C, Ohnishi T, Honda J, Moriya T, Izumi K, Takahashi M, Sasa M, Tangoku A.

Anticancer Res. 2011 Jun;31(6):2389-93.

PMID:
21737670
10.

Immunohistochemical expression of Ki67, c-erbB-2, and c-kit antigens in benign and malignant pheochromocytoma.

Tavangar SM, Shojaee A, Moradi Tabriz H, Haghpanah V, Larijani B, Heshmat R, Lashkari A, Azimi S.

Pathol Res Pract. 2010 May 15;206(5):305-9. doi: 10.1016/j.prp.2010.01.007. Epub 2010 Mar 1.

PMID:
20189725
11.

Immunohistochemical expression of retinoblastoma gene product (Rb), p53 protein, MDM2, c-erbB-2, HLA-DR and proliferation indices in human urinary bladder carcinoma.

Ioachim E, Charchanti A, Stavropoulos NE, Skopelitou A, Athanassiou ED, Agnantis NJ.

Histol Histopathol. 2000 Jul;15(3):721-7.

PMID:
10963116
12.

Expression of DNA topoisomerase I, DNA topoisomerase II-alpha, and p53 in metastatic malignant melanoma.

Lynch BJ, Komaromy-Hiller G, Bronstein IB, Holden JA.

Hum Pathol. 1998 Nov;29(11):1240-5.

PMID:
9824101
13.

KI-67 AND hTERT expression can aid in the distinction between malignant and benign pheochromocytoma and paraganglioma.

Elder EE, Xu D, Höög A, Enberg U, Hou M, Pisa P, Gruber A, Larsson C, Bäckdahl M.

Mod Pathol. 2003 Mar;16(3):246-55.

14.

Correlation between p53, c-erbB-2, and topoisomerase II alpha expression, DNA ploidy, hormonal receptor status and proliferation in 356 node-negative breast carcinomas: prognostic implications.

Rudolph P, Olsson H, Bonatz G, Ratjen V, Bolte H, Baldetorp B, Fernö M, Parwaresch R, Alm P.

J Pathol. 1999 Jan;187(2):207-16.

PMID:
10365096
15.

[Distinction between benign and malignant pheochromocytomas].

Liu TH, Chen YJ, Wu SF, Gao J, Jiang WJ, Lu ZH, Guan J, Wei SZ, Luo YF, Cao JL, Wan JW.

Zhonghua Bing Li Xue Za Zhi. 2004 Jun;33(3):198-202. Chinese.

PMID:
15256107
16.

Influence of chemotherapy on the expression of p53, HER-2/neu and proliferation markers in ovarian cancer.

Nijman HW, Kenemans P, Poort-Keesom RJ, Verstraeten RA, Mensdorff-Pouilly S, Verheijen RH, Melief CJ, Hilgers J, Meijer CJ.

Eur J Obstet Gynecol Reprod Biol. 1999 Apr;83(2):201-6.

PMID:
10391533
18.

The role of prognostic markers (MiB-1, RB, and bcl-2) in the diagnosis of parathyroid tumors.

Vargas MP, Vargas HI, Kleiner DE, Merino MJ.

Mod Pathol. 1997 Jan;10(1):12-7.

PMID:
9021722
19.
20.

Supplemental Content

Support Center